Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sophie C Siegmund

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
PET Clinics|April 30, 2026
Fibroblast Activation Protein: Molecular Imaging and BeyondSophie C Siegmund, Rudolf A Werner, Frederik L Giesel
Cancers|August 28, 2025
Metabolic Imaging in Electrochemotherapy: Insights from FDG-PET Analysis in Metastatic Melanoma-A Pilot StudySophie C Siegmund, Maximilian Deußing, Rudolf A Werner, et al.
Nuklearmedizin. Nuclear Medicine|February 25, 2026
Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and NeckSophie C Siegmund, Sebastian E Serfling, Takahiro Higuchi, et al.
Seminars in Nuclear Medicine|October 16, 2025
Recent Advances and Future Trends of[<sup>18</sup>F]-Labeled PET Agents for Renal ImagingTakahiro Higuchi, Xinyu Chen, Sophie C Siegmund, et al.
Seminars in Nuclear Medicine|December 27, 2025
Current status of FAP therapy in solid tumorsSophie C Siegmund, Emil Novruzov, Eduards Mamlins, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2026
Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [<sup>225</sup>Ac]Ac/[<sup>177</sup>Lu]Lu-PSMA-therapyGabriel T Sheikh, Sophie C Siegmund, Liam Widjaja, et al.
Diagnostics (Basel, Switzerland)|August 28, 2025
Prognostic Value of Automated Bone Scan Index (aBSI) in Patients with mCRPC Undergoing Three vs. Six Cycles of <sup>223</sup>Ra TherapySophie C Siegmund, Harun Ilhan, Antonia Gerull, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 26, 2026
Prognostic Value of Early Follow-Up PSMA PET/CT After 2 Cycles of [<sup>177</sup>Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA DynamicsLiam Widjaja, Johannes Hornfeck, Sophie C Siegmund, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 1, 2025
Refining the clinical utility of [<sup>177</sup>Lu]Lu/[<sup>225</sup>Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancerLiam Widjaja, Johannes Hornfeck, Sophie C Siegmund, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 15, 2026
Estimation of split renal function on PET using the SSTR-targeting radioligands [<sup>18</sup>F]SiTATE, [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>68</sup>Ga]Ga-DOTA-TOC in a theranostic settingMaximilian Tiling, Lena M Unterrainer, Sophie C Siegmund, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
PET Clinics|April 30, 2026
Fibroblast Activation Protein: Molecular Imaging and BeyondSophie C Siegmund, Rudolf A Werner, Frederik L Giesel
Cancers|August 28, 2025
Metabolic Imaging in Electrochemotherapy: Insights from FDG-PET Analysis in Metastatic Melanoma-A Pilot StudySophie C Siegmund, Maximilian Deußing, Rudolf A Werner, et al.
Nuklearmedizin. Nuclear Medicine|February 25, 2026
Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and NeckSophie C Siegmund, Sebastian E Serfling, Takahiro Higuchi, et al.
Seminars in Nuclear Medicine|October 16, 2025
Recent Advances and Future Trends of[<sup>18</sup>F]-Labeled PET Agents for Renal ImagingTakahiro Higuchi, Xinyu Chen, Sophie C Siegmund, et al.
Seminars in Nuclear Medicine|December 27, 2025
Current status of FAP therapy in solid tumorsSophie C Siegmund, Emil Novruzov, Eduards Mamlins, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2026
Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [<sup>225</sup>Ac]Ac/[<sup>177</sup>Lu]Lu-PSMA-therapyGabriel T Sheikh, Sophie C Siegmund, Liam Widjaja, et al.
Diagnostics (Basel, Switzerland)|August 28, 2025
Prognostic Value of Automated Bone Scan Index (aBSI) in Patients with mCRPC Undergoing Three vs. Six Cycles of <sup>223</sup>Ra TherapySophie C Siegmund, Harun Ilhan, Antonia Gerull, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 26, 2026
Prognostic Value of Early Follow-Up PSMA PET/CT After 2 Cycles of [<sup>177</sup>Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA DynamicsLiam Widjaja, Johannes Hornfeck, Sophie C Siegmund, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 1, 2025
Refining the clinical utility of [<sup>177</sup>Lu]Lu/[<sup>225</sup>Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancerLiam Widjaja, Johannes Hornfeck, Sophie C Siegmund, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 15, 2026
Estimation of split renal function on PET using the SSTR-targeting radioligands [<sup>18</sup>F]SiTATE, [<sup>68</sup>Ga]Ga-DOTA-TATE and [<sup>68</sup>Ga]Ga-DOTA-TOC in a theranostic settingMaximilian Tiling, Lena M Unterrainer, Sophie C Siegmund, et al.
Pageof 2